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Exome Sequencing Identifies a DYNC1H1 Mutation
in a Large Pedigree with Dominant Axonal
Charcot-Marie-Tooth Disease
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Thalia Antoniadi,4 Maggie Williams,4 Cath King,2 Lynn Greenhalgh,2 Ruth Newbury-Ecob,2
and Sian Ellard1,*
Charcot-Marie-Tooth disease is characterized by length-dependent axonal degeneration with distal sensory loss and weakness, deep-
tendon-reflex abnormalities, and skeletal deformities. It is caused bymutations inmore than 40 genes.We investigated a four-generation
family with 23 members affected by the axonal form (type 2), for which the common causes had been excluded by Sanger sequencing.
Exome sequencing of three affected individuals separated by eight meioses identified a single shared novel heterozygous variant,
c.917A>G, in DYNC1H1, which encodes the cytoplasmic dynein heavy chain 1 (here, novel refers to a variant that has not been seen
in dbSNP131or the August 2010 release of the 1000 Genomes project). Testing of six additional affected family members showed cose-
gregation and a maximum LOD score of 3.6. The shared DYNC1H1 gene variant is a missense substitution, p.His306Arg, at a highly
conserved residue within the homodimerization domain. Three mouse models with different mutations within this domain have previ-
ously been reported with age-related progressive loss of muscle bulk and locomotor ability. Cytoplasmic dynein is a large multisubunit
motor protein complex and has a key role in retrograde axonal transport in neurons. Our results highlight the importance of dynein and
retrograde axonal transport in neuronal function in humans.Charcot-Marie-Tooth (CMT) disease is the most common
inherited neuromuscular disorder and has an estimated
prevalence of 1 in 2500. It is a chronic motor and sensory
polyneuropathy characterized by distal muscle weakness
and atrophy that might be associated with sensory loss,
depressed tendon reflexes, and pes cavus. There are two
main forms: the demyelinating type 1 that affects myelin
(CMT1) and the axonal type 2 affecting the nerve axon
(CMT2). Autosomal-dominant inheritance is most com-
mon, but autosomal-recessive and X-linked forms are
also seen. There is considerable genetic heterogeneity,
and more than 40 genes or loci have been identified.1 We
studied a four-generation family with 23 members affected
(Figure 1) with CMT2, characterized by delayed motor
milestones and/or an abnormal gait. Sanger sequencing
excluded the genes commonly associated with CMT2;
MPZ (MIM 159440), NEFL (MIM 162280), MFN2 (MIM
608507), and LMNA (MIM 150330). Male tomale transmis-
sion excluded GJB1 (MIM 304040), and after sequencing of
PMP22 (MIM 601097) failed to identify a pathogenicmuta-
tion, we employed a whole-exome sequencing strategy.
Exonic sequences from three affected individuals (IV-2,
-7, and -14) separated by eight meioses were enriched
from genomic DNAwith Agilent’s SureSelect whole-exome
kit (version 1) as recommended by the manufacturers
except that gDNA fragmentation was carried out with a
Diagenode Bioruptor. After hybridization reactions, cap-
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paired-end reads. We used Novoalign (Novocraft Technol-
ogies) to align sequence reads to the hg19 reference
genome and removed any duplicate reads from subsequent
analyses. Seventy-six percent of targeted Consensus
Coding Sequence project (CCDS) exonic bases were
covered with at least 20 reads with an average coverage
of 703 (Table S1, available online). We used Samtools2 to
call SNPs and indels. Annovar3 was used for annotation
of variants, and we filtered variants by using dbSNP131,
1000 Genomes (August 2010 release), and our in-house
(exome data from 11 individuals of European descent)
databases. Informed consent was obtained from all partic-
ipants.
We assumed a rare autosomal-dominant model of inher-
itance, and after filtering, we found the three individuals
had 177, 192, and 199 novel heterozygous variants (here,
novel refers to a variant that has not been seen in
dbSNP131or the August 2010 release of the 1000 Genomes
project). annotated as missense, nonsense, frameshift, or
splice site (Table 1 and Table S2). Four to six variants
were shared by each pair, but only one variant in
DYNC1H1 (NM_001376.4 [MIM 600112]) was shared by
all three (the number expected on the basis of the number
of meioses separating these individuals). Testing of six
additional affected family members by Sanger sequencing
showed cosegregation with a maximum LOD score of
3.6 (see Figure 1). The variant was not present in 322rsity of Exeter, Exeter EX2 5AD, UK; 2Clinical Genetics Department, Univer-
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Figure 1. Partial Pedigree Showing Mutation
Status
Open symbols represent unaffected individuals;
filled squares represent affected males and filled
circles affected females. Individual generations
are numbered with roman numerals on the left.
Individuals heterozygous for the p.His306Arg
mutation are indicated as N/M. For the LOD-
score calculation we assumed a rare autosomal-
dominant model with a disease-allele frequency of 0.0001 and phenocopy rate of 0. The mutant DYNC1H1 allele is rare (frequency
<0.001); because we only tested affected individuals to avoid issues of predictive testing and variable penetrance and because there
are 12 meioses separating the nine sequenced individuals, the LOD score for the variant can be approximated as log10(0.512) ¼ 3.6.ethnically matched control chromosomes. The shared
DYNC1H1 variant is a missense change, p.His306Arg
(c.917A>G), at a highly conserved residue (Figure S1)
within the homodimerization domain of cytoplasmic
dynein heavy chain 1.
Cytoplasmic dynein is a large multisubunit motor
protein complex that has a range of cellular functions. In
particular, it is the primary motor protein responsible for
retrograde axonal transport in neurons—the movement
of cargo such as organelles from the cell periphery to the
cell body along cytoskeletal microtubules. A homodimer
of the 532 kDa cytoplasmic dynein heavy chain 1 forms
the core of dynein and is responsible for the protein
complex binding to and moving along microtubules.4
Other subunits of dynein include the intermediate, light-
intermediate, and light chains, thought to be responsible
for interacting with cargo and maintaining the stability
of the complex.4
Our results are corroborated by previous animal studies
that have implicated disruption ofDync1h1 in neuropathic
disease. Legs at odd angles (Loa)5, Cramping 1 (Cra1)5 and
Sprawling (Swl)6 are mouse phenotypes that arose from
N-ethyl-N-nitrosourea (ENU) or radiation-induced muta-
genesis. Heterozygous mice have age-related progressive
loss of muscle bulk and locomotor ability without a major
reduction in life span.5,6 Although there are differences
between the mouse models, and indeed different patho-
genesis suggested for the same mouse model by different
researchers,7,8 the mouse phenotype is broadly similar to
that observed in our family. Affected patients typically
have delayed motor milestones and/or an abnormal gait
along with early-onset slowly progressive distal lower
limb weakness and wasting with pes cavus deformity (see
Figure S2). Clinical features of the best characterized family
members are shown in Table 2. Upper limb involvement isTable 1. Novel Heterozygous Missense, Nonsense, Frameshift, or
Splice-Site Variants
Individuals Shared
IV-2 IV-7 IV-14 IV-2 and IV-7 IV-2 and IV-14 IV-7 and IV-14 All
177 192 199 6 5 4 1
Number of novel heterozygous variants in the exome of each sequenced indi-
vidual and the number shared across the individuals. Here, ‘‘novel’’ refers to
a variant that has not been seen in dbSNP131, the August 2010 release of
the 1000 Genomes project, or 11 in-house control exomes processed with
the same laboratory and analysis pipeline.
The Americless common, and ambulation is usually maintained
through adulthood. Nerve conduction studies are within
the normal range, sural nerve biopsies demonstrated
minimal changes suggestive of increased axon degenera-
tion, and muscle biopsies show findings consistent with
secondary muscle involvement due to denervation (see
Table 3). Transient paresthesia and neuropathic lower
limb pains are also reported by several family members,
typically those more severely affected. Although the core
features consistent with CMT2 are seen across the family,
there is significant variability in other findings: reflexes
might be lost or preserved; fine touch, vibration sense,
and proprioception are retained in many family members
but lost in some; atypical features, such as predominant
proximal muscle involvement, periscapular wasting and
weakness, spinal and hip problems, and a broad-based
waddling gait, are also found in a few.
The mouse mutations of Dync1h1 (NM_030238.2;
c.1739T>A[p.Phe580Tyr] inLoa;c.3164A>G[p.Tyr1055Cys]
in Cra; and a 9 bp deletion, c.3119_3127delGCATAGTGA
[p.(Gly1040_Thr1043delinsAla)], in Swl) also affect resi-
dues within the homodimerization region of the dynein
stem domain (Figure 2). The embryonic lethality of the
homozygous Dync1h1 null mouse but normal phenotype of
heterozygous null mice9 raises the possibility of a domi-
nant-negative effect for the neuropathic mutations. Given
the multiple functions of dynein, the exact mechanism by
which these mutations cause disease is still unclear. One
recent study of the Cra mouse suggested an impact on
synapse structure at neuromuscular junctions,7 whereas
another proposed an effect on striatal neurons.8 However,
a recent report with single-molecule and live-imaging tech-
niques in the Loa mouse strongly suggested that defects
in dynein motor processivity play a key role in disease
causation.10Measurement of retrograde run-lengths (periods
of uninterrupted motion) showed a marked reduction in
the ability of mutant dynein to move along microtubules
both in vitro and in vivo.10 Therewas also evidence of altered
interaction between the dynein motor and stem domains,
and this interaction raises the possibility of motor domain
miscoordination.10 This reduction in processivity could
explain the observed neuropathy phenotype because the
neurons most affected will be those with long axons such as
the motor and sensory neurons.
Mutations in other axonal transport genes cause related
neuronal diseases. Autosomal-dominant mutations in thean Journal of Human Genetics 89, 308–312, August 12, 2011 309
Table 2. Clinical Features of Selected Family Members
Patient Presentation Features
II 10 delayed motor milestones; recurrent surgery to feet
and ankles in childhood
reduced power and wasting in distal upper and lower limbs; pes cavus;
reduced proprioception, normal vibration sense; reflexes normal
II 13 pes cavus at birth; recurrent surgery to feet
and ankles in childhood
distal lower limb weakness and wasting; pes cavus; reduced proprioception,
pin-prick, fine touch and vibration sense; reflexes normal; significant
neuropathic pain; depression and paraphrenia; extrapyramidal features
probably due to antipsychotics
III 4 delayed motor milestones and recurrent falls mild distal lower limb weakness and wasting; pes cavus; reduced fine touch,
other sensory modalities normal; reflexes normal
III 7 presented at age 11 with difficulties running mild distal lower limb weakness and paresthesia; pes cavus; all sensory
modalities reduced; reduced reflexes
III 9 presented at age 14 with frequent falls distal upper and lower limb weakness and wasting (LL > UL); pes cavus;
all sensory modalities reduced; reduced ankle reflexes
III 11 talipes at birth; delayed motor milestones distal lower limb weakness and wasting; pes cavus; retained reflexes
and sensation; retinoblastoma
III 14 delayed motor milestones broad-based gait; distal lower limb weakness and wasting; reduced reflexes;
sensory modalities retained; mild intention tremor; strabismus
III 17 abnormal gait in early childhood minimally reduced power and wasting in distal lower limbs; normal reflexes
and sensation; no pes cavus
III 18 delayed motor milestones; speech delay proximal and distal lower limbs weakness and wasting and scapula wasting;
pes cavus and bilateral foot drop; reflexes reduced; paraesthesia but
objectively normal sensation; significant neuropathic pain and back pain
III 21 delayed motor milestones and learning difficulties proximal and distal lower limb weakness and wasting; reduced reflexes;
normal sensory modality testing; lumbar lordosis and reduced hip
movements; behavioral problems including school exclusions
IV 2 abnormal gait and falls in early childhood;
global developmental delay
distal lower limb weakness; no pes cavus; normal reflexes and sensation
IV 7 delayed motor milestones; speech delay
and learning difficulties
broad-based gait; distal lower limb weakness and wasting; no pes cavus; reduced
reflexes; reduced proprioception, other sensory modalities normal; lumbar lordosis
and reduced hip movements; Achilles-tendon-lengthening operations
IV 14 delayed motor milestones Waddling gait; proximal lower limb weakness more dominant than distal lower
limb weakness; no pes cavus; reduced knee reflexes; sensory modalities normal;
lumbar lordosisp150 subunit of dynactin (also known as dynein activator)
cause a form of motor neuron disease (MIM 601143)11
and a heterozygous KIF1B (MIM 605995) mutation
results in CMT2A (MIM 118210).12 KIF1B is a member of
the kinesin superfamily of motor proteins that are
involved in anterograde axonal transport (taking cargo
from the cell body to the periphery of the neurons).
Mutations in other kinesin genes have been shown to
cause neuronal disease, for example KIF5A (MIM 602821)
mutations cause hereditary spastic paraplegia (MIM
604187).13 Our findings provide further evidence of
the importance of motor proteins and in particular retro-
grade axonal transport in the normal functioning of
neurons.
Our work has used exome sequencing in selected indi-
viduals from a large pedigree to identify a disease-causing
mutation. Charcot-Marie-Tooth disease can be caused by
mutations in over 40 genes, and screening with Sanger
sequencing is costly and time consuming. DYNC1H1
(14q32.31) is not within a known region of linkage for
CMT. An alternative approach,14,15 linkage analysis fol-
lowed by candidate gene Sanger sequencing, utilized in310 The American Journal of Human Genetics 89, 308–312, August 1other studies would still have required the sequencing of
at least the 78 exons of DYNC1H1.
In summary, we have identified amutation inDYNC1H1
that causes Charcot-Marie-Tooth disease by using exome
sequencing in a large dominant pedigree. The mouse
models also harboring mutations in the homodimeriza-
tion domain of cytoplasmic dynein heavy chain 1 support
the pathogenicity of the human DYNC1H1 mutation
and give valuable insights to pathophysiology. These
results highlight the importance of dynein and retrograde
axonal transport in neuronal function in humans.
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Table 3. Clinical Investigation Results
Patient
Age at
Study
Motor Sensory
Electromyography Sural Nerve Biopsy Muscle Biopsy
Right Peroneal Right Tibial Right Sural Right Sup Peroneal
Amplitude
(mV)
Velocity
(m/s)
Amplitude
(mV)
Velocity
(m/s)
Pk-Pk
(mV)
Velocity
(m/s)
Pk-Pk
(mV)
Velocity
(m/s)
II 10 29 – – 3.85 46 20 39 – – chronic denervation – –
II 13 31 – – 4.3 51 12 41 – – central neuronal
atrophy
– severe connective
tissue replacement
II 15 36 normal normal normal normal normal normal normal normal – indolent axon
degenerative process
with some evidence
of fiber regeneration
consistent with a
diagnosis of HMSN
type 2
–
III 4 25 2.0 56.6 8.9 – 20.3 42.9 13.3 45.5 normal – –
III 14 28 5.4 44.2 7.1 39.6 8.6 37.7 7.8 40 vastus medialis MUPs
enlarged otherwise
normal
– –
III 17 20 normal normal normal normal normal normal normal normal – – –
III 18 22 2.9 44 11.5 – 7 28 15 35 mild degree of large fiber
axonal sensory motor
peripheral neuropathy
– –
III 21 2 normal normal normal normal normal normal normal normal interference pattern
nonspecifically
abnormal, occasional
units up to 6 mV
– –
IV 7 5 not
performed
not
performed
not
performed
not
performed
not
performed
not
performed
not
performed
not
performed
– – atrophic fibers consistent
with chronic partial
denervation
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Figure 2. Schematic Representation of Human
DYNC1H1
The N-terminal region of DYNC1H1 is repre-
sented by a horizontal black bar, and the stem
domain (amino acids 53–1867) is indicated by
a bracket above. Residues involved in DYNC1H1
dimerization (300–1140) are shown by a light
blue bar; open boxes represent binding regions
for intermediate (DYN1I; residues 448–703, solid
line) and light-intermediate (DYN1LI; residues 651–802, broken line) chains, respectively. The motor domain (amino acids 1868–4646)
is indicated by the orange shaded area; the seven ATPase domains are represented by circles, whereas the horizontal bar indicates the
stalk region. The equivalent positions of mutations in three mouse models, Loa, Swl, and Cra1, are shown below the figure along
with the p.His306Arg mutation identified in the family reported here. Note that the human protein contains two additional glycine resi-
dues at position 7 relative to mouse Dync1h1, that is numbering of equivalent residues in human DYNC1H1 is 2 higher than in mouse
models. Phe582 is within a highly conserved domain responsible for binding the dynein intermediate chains as well as homodimeriza-
tion.4 The 9 bp Swl deletion and Cra p.Tyr1057Cys mutation are outside the dynein intermediate-chain binding region but within the
putative homodimerization domain.4 Numbering of amino acids is taken from Tynan et al.16 and the UniProtKB entry for human
DYNC1H1 (identifier Q14204).Received: May 19, 2011
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